Advanced glycosylation end products in patients with diabetic nephropathy - PubMed (original) (raw)
. 1991 Sep 19;325(12):836-42.
doi: 10.1056/NEJM199109193251202.
Affiliations
- PMID: 1875967
- DOI: 10.1056/NEJM199109193251202
Free article
Advanced glycosylation end products in patients with diabetic nephropathy
Z Makita et al. N Engl J Med. 1991.
Free article
Abstract
Background: Glucose reacts nonenzymatically with proteins in vivo, chemically forming covalently attached glucose-addition products and cross-links between proteins. The excessive accumulation of rearranged late-glucose-addition products, or advanced glycosylation end products (AGEs), is believed to contribute to the chronic complications of diabetes mellitus.
Methods: To elucidate the relation of AGEs to diabetic complications, we used a radioreceptor assay to measure serum and tissue AGEs in diabetic (Types I and Type II) and nondiabetic patients with different levels of renal function. Serum AGEs were measured as a low-molecular-weight (less than or equal to 10 kd) peptide fraction and a high-molecular-weight (greater than 10 kd) protein fraction.
Results: The mean (+/- SD) AGE content of samples of arterial-wall collagen from 9 diabetic patients was significantly higher than that of samples from 18 nondiabetic patients (14.5 +/- 5.2 vs. 3.6 +/- 1.5 AGE units per milligram, P less than 0.001). Moreover, diabetic patients with end-stage renal disease had almost twice as much AGE in tissue as diabetic patients without renal disease (21.3 +/- 2.8 vs. 11.5 +/- 1.9 AGE units per milligram, P less than 0.001). The AGE levels in both serum fractions were elevated in the patients with diabetes, and the levels of AGE peptides correlated directly with serum creatinine (P less than 0.001) and inversely with creatinine clearance (P less than 0.005), suggesting that levels of AGE peptides increased with the severity of diabetic nephropathy. In six patients with diabetes who required hemodialysis, the levels of AGE peptides were five times higher than in eight normal subjects (82.8 +/- 9.4 vs. 15.6 +/- 3.4 AGE units per milliliter, P less than 0.001). In another group of diabetic patients the mean serum creatinine level, which decreased by 75 percent during a session of hemodialysis, whereas the level of AGE peptides decreased by only 24 percent. Serum levels of AGE peptides were normal in two patients with normal serum creatinine levels after renal transplantation.
Conclusions: AGEs accumulate at a faster-than-normal rate in arteries and the circulation of patients with diabetes; the increase in circulating AGE peptides parallels the severity of renal functional impairment in diabetic nephropathy.
Comment in
- Toward a basic understanding of diabetic complications.
Steffes MW, Mauer SM. Steffes MW, et al. N Engl J Med. 1991 Sep 19;325(12):883-4. doi: 10.1056/NEJM199109193251209. N Engl J Med. 1991. PMID: 1875974 No abstract available.
Similar articles
- The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. Shimoike T, et al. Metabolism. 2000 Aug;49(8):1030-5. doi: 10.1053/meta.2000.7738. Metabolism. 2000. PMID: 10954022 - Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Münch G, Bahner U, Schinzel R. Gerdemann A, et al. Clin Nephrol. 2000 Oct;54(4):276-83. Clin Nephrol. 2000. PMID: 11076103 - A novel advanced glycation index and its association with diabetes and microangiopathy.
Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V. Sampathkumar R, et al. Metabolism. 2005 Aug;54(8):1002-7. doi: 10.1016/j.metabol.2005.02.017. Metabolism. 2005. PMID: 16092048 Clinical Trial. - Serum advanced glycosylation end products: a new class of uremic toxins?
Vlassara H. Vlassara H. Blood Purif. 1994;12(1):54-9. doi: 10.1159/000170145. Blood Purif. 1994. PMID: 7986476 Review. - Advanced glycation end products and the kidney.
Bohlender JM, Franke S, Stein G, Wolf G. Bohlender JM, et al. Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59. doi: 10.1152/ajprenal.00398.2004. Am J Physiol Renal Physiol. 2005. PMID: 16159899 Review.
Cited by
- Update on blood pressure control and renal outcomes in diabetes mellitus.
Joven MH, Anderson RJ. Joven MH, et al. Curr Diab Rep. 2015 Jul;15(7):44. doi: 10.1007/s11892-015-0613-6. Curr Diab Rep. 2015. PMID: 25990743 Review. - Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1.
Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J. Vlassara H, et al. J Clin Endocrinol Metab. 2009 Nov;94(11):4483-91. doi: 10.1210/jc.2009-0089. Epub 2009 Oct 9. J Clin Endocrinol Metab. 2009. PMID: 19820033 Free PMC article. - Potential Diagnostic Hemorheological Indexes for Chronic Kidney Disease in Patients With Type 2 Diabetes.
Lee H, Na W, Lee SB, Ahn CW, Moon JS, Won KC, Shin S. Lee H, et al. Front Physiol. 2019 Aug 20;10:1062. doi: 10.3389/fphys.2019.01062. eCollection 2019. Front Physiol. 2019. PMID: 31481899 Free PMC article. Review. - Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus.
Hogan M, Cerami A, Bucala R. Hogan M, et al. J Clin Invest. 1992 Sep;90(3):1110-5. doi: 10.1172/JCI115928. J Clin Invest. 1992. PMID: 1522220 Free PMC article. - LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.
Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S. Figarola JL, et al. Diabetologia. 2003 Aug;46(8):1140-52. doi: 10.1007/s00125-003-1162-0. Epub 2003 Jul 5. Diabetologia. 2003. PMID: 12845431
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical